Digistain®

Digistain® is at the forefront of digital transformation in cancer diagnostics, providing innovative solutions for radically faster gold standard risk scoring analytics at a dramatically lower cost. Digistain®'s patented risk profiling test for hormone receptor-positive breast cancer patients has been approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA). The easy-to-read report offers both physicians and patients clear, actionable information to help determine the best course of treatment and whether cytotoxic therapy in addition to hormone therapy is required.

Located at Unit 101, Interchange Business Park, Howard Way, Newport Pagnell, MK16 9PY, GB, Digistain® offers a digital solution to cancer grading and prognosis. Based on 15 years of research and development, the MHRA-approved Digistain® technology continues to set new standards in the field, providing critical insights for informed decision-making in cancer treatment.

Digistain® is dedicated to advancing cancer care through cutting-edge digital solutions. We invite the company's management to create a customized and exclusive company showcase and product listing on our platform, further highlighting their groundbreaking work in biotechnology research.